Best of Lipid Forum®: Examining the Role of Lp(a) as a Risk Factor in Atherosclerotic Cardiovascular Disease

This continuing education activity is provided by
and

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Overview

Lipoprotein(a) [Lp(a)] is a low-density lipoprotein particle that is associated with poor cardiovascular prognosis due to its pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties. Unfortunately, traditional lipid-lowering therapy does not provide sufficient Lp(a) reduction. High levels of Lp(a) are an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD) through mechanisms associated with increased atherogenesis, inflammation, and thrombosis. Despite its demonstrated contribution to ASCVD burden, there is a lack of standardization and harmonization of assays, no universal guidelines for diagnosing and providing risk assessment, and few targeted treatments to lower Lp(a). In this CE program, expert faculty review the pathophysiology and accurate measurement of Lp(a), implications of increased Lp(a) levels on cardiovascular risk, as well as current and emerging therapeutic approaches to manage patients with elevated Lp(a). This activity incorporates didactic presentations covering the pathophysiology of Lp(a); investigates guidelines, screening, and patient identification; explores the measurement of Lp(a), and finally discusses both current and emerging therapies for Lp(a) reduction.

ACTIVITY CHAIR

Alan S. Brown, MD, FACC, FAHA, FASPC, MNLA
Past President, National Lipid Association
Director, Division of Cardiology
Advocate Heart Institute at Advocate Lutheran General Hospital
Park Ridge, IL
Clinical Associate Professor, Loyola Stritch School of Medicine
Chicago, IL

FACULTY

Marlys Koschinsky, PhD, FAHA, FNLA, FACC, FACHS
Professor, Department of Physiology and Pharmacology
Scientist, Robarts Research Institute
Schulich School of Medicine and Dentistry
University of Western Ontario
London, Ontario Canada

Patrick M. Moriarty, MD, FACP, FACC, FNLA, FESC
Professor of Medicine and Clinical Pharmacology
Director of Atherosclerosis and Lipid-apheresis Center
University of Kansas Medical Center
Kansas City, KS

Jessica M. Peña, MD, MPH, FNLA, FACC
Associate Professor of Clinical Medicine
Associate Professor of Medicine in Clinical Radiology
Weill Cornell Medical College
New York, NY

James A. Underberg, MD, MS, FACP, FACPM, FASH, MNLA
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for CV Prevention
Director Bellevue Hospital Lipid Clinic
Past-President National Lipid Association
Past-President American Board of Clinical Lipidology
Diplomate American Board of Clinical Lipidology
New York, NY

REVIEWERS/PLANNERS

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Linda A. Giarraputo, BS, PA-C
Jasmine Gonzalvo, PharmD
Ashley H. Meredith, PharmD, MPH, BCACP

Credit Designation

PHARMACY
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-23-005-H01-P, 2.0 contact hours (0.20 CEUs). Release Date: 04/30/2023 Expiration Date: 04/29/2024.

This enduring material is approved for 1 year from the date of original release, April 30, 2023, to April 29, 2024.

How to Participate in This Activity and Obtain CE Credit

To participate in this activity, you must read the objective(s), answer the polling and pretest question(s), view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 6 out of 8 of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Purdue University College of Pharmacy will provide pharmacist credit claim information directly to the ACPE through CPE Monitor within approximately 30-days of activity completion. No certificate will be issued to pharmacists. For proof of credit, you may access your statement or transcript in your NABP e-profile.

Disclosures

Purdue University College of Pharmacy and Vindico Medical Education adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Activity Chair and Faculty report the following relevant financial relationships

Alan S. Brown, MD, FACC, FAHA, FASPC, MNLA
Consultant: Amgen, Esperion, Ionis, Novartis, Regeneron
Speaker Contracted by Ineligible Company: Amarin, Amgen, Esperion, Regeneron

Marlys Koschinsky, PhD, FAHA, FNLA, FACC, FACHS
Advisor: Novartis Canada
Consultant: Ayma Therapeutics
Independent Research Contractor: Abcentra

Patrick M. Moriarty, MD, FACP, FACC, FNLA, FESC
Advisor: Novartis
Consultant: Amgen, Esperion, HDL Therapeutics, Regeneron
Independent Research Contractor: Aegerion Pharmaceuticals, Amgen, Esperion, Ionis, Kowa, Novartis, Regeneron

Jessica M. Peña, MD, MPH, FNLA, FACC
No relevant financial relationships to disclose.

James A. Underberg, MD, MS, FACP, FACPM, FASH, MNLA
Advisor: Pfizer, Novartis
Consultant: Amgen
Speaker Contracted by Ineligible Company: Amarin, Ambry, Amgen, Amryt, Esperion, GBinsight, Novartis, Regeneron
Independent Research Contractor: Amryt

Planners/Reviewers report the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Linda A. Giarraputo, BS, PA-C
No relevant financial relationships to disclose.

Jasmine Gonzalvo, PharmD
No relevant financial relationships to disclose.

Ashley H. Meredith, PharmD, MPH, BCACP
No relevant financial relationships to disclose.

PURDUE UNIVERSITY COLLEGE OF PHARMACY AND Vindico Medical Education Staff:

No relevant financial relationships to disclose.

Signed disclosures are on file at Purdue University College of Pharmacy and Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

The material presented at or in any Vindico Medical Education and Purdue University College of Pharmacy continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education or Purdue University College of Pharmacy. Neither Vindico Medical Education, Purdue University College of Pharmacy, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CPE Questions?

Contact Pharmacy-CECR@Purdue.edu